Members of the U.S. Senate and Congress are no strangers to making highly lucrative and frequently unorthodox stock picks, with their timing and success rates being such that many firmly believe they are acting on insider information.
While Nancy Pelosi is the most recognizable among the politician-traders – thanks to both her impressive investing skill and her tenure as the Speaker of the House – Senator Tommy Tuberville is no laggard when it comes to stock market returns.
Late in March, in fact, Tuberville made one of his most suspicious – and, as it turns out, one of his most successful – investments when he acquired the stock of a relatively small company known as Humacyte (NASDAQ: HUMA).
Picks for you
The suspicious and successful Humacyte trade
There are several rules of thumb when it comes to politicians’ investments: they tend to purchase either large-cap blue chips, municipal bonds, or stocks of unknown firms they have substantial influence over.
The third category provided its most ironic and, perhaps, offensive example late in 2023 when the Chair of the Ethics Committee made a substantial investment in an online gambling company.
Tuberville’s Humacyte purchase also arguably falls under the third category. For starters, it is a relatively small medical company that specializes in regenerative medicine with a particular focus on treating combat wounds.
The company has, in recent years, been most active on the battlefields of Ukraine.
For his part, Tuberville sits on the Senate Armed Services Committee.
Since the Senator disclosed his investments, HUMA shares have risen approximately 44%, while they are slightly less in the green since he acquired his latest round of Humacyte stock in late March – 11.99%.
Humacyte stock price chart
While an 11.99% rise in just over a month might not appear that impressive – at least when compared to how some of the other politicians’ trades went – it is worth pointing out that the investment was made after HUMA failed to hold its February rally and near its subsequent bottom.
Indeed, since the start of the year, Humacyte shares are, overall, 41.52% in the green and though Tuberville disclosing the investment did not apparently kickstart the most recent rally, it seemingly helped confirm it.
Finally, more recent trading has been very positive for HUMA as it is up 35.88% in the last 30 days and 5,14% on the weekly chart. Humacyte price today stands at $4.09 after ending tha latest full session – Monday, April 29 – 2.51% in the green.
Buy stocks now with eToro – trusted and advanced investment platform
Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
